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Background. Characteristics, associated factors, and survival probability of toxoplasmic encephalitis (TE) in the
era of advanced highly active antiretroviral therapy (HAART) have not been fully clarified.
Methods. Data for 205 individuals with acquired immunodeficiency syndrome (AIDS)–related TE were derived
from the Italian Registry Investigative NeuroAIDS database, and the cases were studied longitudinally to evaluate
prevalence, clinical characteristics, and survival. Moreover, the relationship between the occurrence of TE and exposure
to antiretroviral therapy and to TE prophylaxis was evaluated.
Results. With an overall prevalence of 26%, TE represented the most frequent neurological disorder in the
cohort. Female sex, severe immunodeficiency, and absence of primary TE prophylaxis significantly increased the risk
of TE, and previous exposure to antiretroviral therapy reduced the probability of disease occurrence. Thirty-six percent
of patients who had received antiretroviral therapy developed TE, although in most of these cases, the patient
experienced failure of antiretroviral therapy. Of note, 66% of patients who had experienced antiretroviral therapy did
not receive prophylaxis for TE at TE diagnosis.
The 1-year probability of that infection with human immunodeficiency virus (HIV) would progress or that death
would occur after TE was 40% and 23%, respectively. Cognitive symptoms, low CD4+ cell count, not receiving HAART
after TE, and initiating HAART 12 months after TE diagnosis were all significantly associated with an increased
probability of progression of HIV infection. Not receiving HAART after diagnosis negatively affected survival.
Conclusions. TE remains a highly prevalent disorder of the central nervous system, even in the late HAART era,
particularly among severely immunosuppressed patients and in absence of prophylaxis. Considering that persons with
TE have a high probability of early death, prophylaxis should be maintained in immunosuppressed patients who
experience failure of antiretroviral therapy, and HAART should be initiated as soon as possible after TE diagnosis.
Toxoplasmic encephalitis (TE) is a life-threatening in-
fection of the CNS that is typically observed in the later
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stages of HIV infection [1]. In the early 1990s, TE was
the most prevalent focal brain disorder among HIV-
infected patients, with a mean annual incidence of
∼0.4–0.7 events per 100 person-years [2, 3] and oc-
curring more frequently in patients with low CD4+ cell
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counts [3]. In the years 1992–1996, because of the widespread
use of prophylactic regimens, a decrease in epidemiological
trends of disease was observed [3–5].
The advent of HAART has resulted in a reduction in the
incidence of most opportunistic infections [6–8] and also in
the incidence of CNS disorders, as confirmed by a recent Eu-
ropean cohort study [5, 9–11]. Concerning TE, a trend towards
a decreased incidence rate in the first years in which HAART
was widely available, compared with the pre-HAART years, was
reported in 2 large cohort studies [5, 12]. Of note is that TE
prevalence among AIDS-related focal brain disorders appeared
to stabilize during the HAART era, after a decrease was observed
during the pre-HAART period [9].
Before the availability of HAART, injection drug use, pre-
vious AIDS-defining events, decreased CD4+ cell count, lack of
antiretroviral therapy, and lack of prophylaxis against infection
with Toxoplasma species were all reported as being significantly
associated with an increased risk of developing TE [3, 12]. At
the beginning of the HAART era, lack of exposure to HAART
and prophylaxis, as well as persistent CD4+ cell depletion, sig-
nificantly increased the risk of disease [12].
The proportion of TE-associated deaths decreased from 3.5%
of all HIV infection–related deaths in 1992 to 1.9% in 1998,
with a percentage reduction greater than that observed in HIV–
related deaths overall [13]. Although the improvement in sur-
vival of HIV-infected patients due to HAART has largely been
documented [14–16], specific evaluations about survival and
associated factors in HIV-infected patients with TE have not
been carried out until now.
The aim of the present study was to assess prevalence, clinical
characteristics, and survival probability of patients with newly
diagnosed cases of TE in the advanced HAART era. Moreover,
the relationship between occurrence of TE and previous ex-
posure to antiretroviral therapy and prophylaxis against infec-
tion with Toxoplasma species was evaluated.
METHODS
Design of the study and diagnostic criteria. The Italian Reg-
istry Investigative NeuroAIDS (IRINA) study is a prospective
multicenter study that involves 45 Italian infectious diseases
centers that specialize in the treatment of HIV-infected patients.
The main aim of the survey is to analyze epidemiological
changes in and document the natural history of HIV-related
neurological disorders in the era of HAART. The second aim
of the IRINA study is to evaluate survival probability, baseline
values, and longitudinal survival-associated factors in relation-
ship to antiretroviral exposure before and after diagnosis of
neurological disorders [17]. The study started in January 2000
and included all patients with HIV-related disorders of the CNS
who were consecutively observed in the participating centers.
For each case of neurological disease, the center is required to
fill out a notification sheet with data that includes demographic
and epidemiological variables, history of HIV infection and
receipt of antiretroviral therapy, clinical and radiological char-
acteristics, and diagnostic criteria. Every 6 months, a follow-
up sheet is filled out with information regarding treatment
outcome and survival.
Statistical analysis. The current study was based on all
cases documented as part of the IRINA study from January
2000 through December 2002. To avoid selection bias, the anal-
ysis was restricted to persons experiencing a first episode of TE
and to those with 1 concomitant CNS disorder. Diagnosis of
TE was performed in agreement with the 1993 Centers for
Disease Control and Prevention (CDC) classification, and both
histological and presumptive diagnoses were accepted. Pre-
sumptive diagnosis was based on compatible clinical and/or
neuroradiological signs, serological test results positive for Tox-
oplasma species, or response to specific therapy [18].
The association between the presence of TE and demo-
graphic, clinical, and radiological characteristics was explored
by contingency tables and was estimated calculating ORs2 2
with 95% CIs. Statistical significance was tested by Fisher’s exact
test or by univariate logistic regression analysis. A multivariable
logistic regression model that included all significant covariates
found by univariate analysis was used to calculate adjusted ORs
and to detect factors predictive of TE.
To analyze the effect of exposure to antiretroviral therapy,
patients were stratified in 2 groups according to exposure to
antiretroviral treatment. The first group included patients who
were antiretroviral therapy naive at TE diagnosis, and the sec-
ond group included patients who were receiving HAART at TE
diagnosis or had experienced antiretroviral therapy. Differences
between the 2 groups were assessed using 1-way analysis of
variance or Fisher’s exact test and logistic regression, as ap-
propriate, for continuous and categorical variables, respectively.
Survival probabilities were estimated using the Kaplan-Meier
method and log-rank test. A Cox proportional hazards model
was employed to define crude and adjusted relative hazards
associated with death and clinical progression of disease. The
multivariable model was adjusted for baseline and time-de-
pendent covariates that significantly influenced survival and
clinical progression on univariate analysis. All P values .05
were considered to be statistically significant. Statistical analysis
was performed using the software package SPSS, version 11.0.1
(SPSS).
RESULTS
Prevalence and characteristics of TE. From January 2000
through December 2002, of the 805 persons with CNS disorders
documented by the IRINA study, 211 (26.2%) had a first ep-
isode of TE. Of these, 205 patients without other concomitant
CNS disorders were included in the analysis. A bioptic or au-
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Table 1. Demographic, clinical, epidemiological, and radiological features of
patients with and without toxoplasmic encephalitis (TE).
Variable
Patients
with TE
(n p 205)
Patients
without TE
(n p 568) P
Male sex 135 (66.0) 438 (77.1) .002
Age, mean years  SD 39  7.5 41  9.5 !.001
Transmission group
IDU 76 (37.1) 268 (47.2) .012
MSM 24 (11.7) 61 (10.7)
Heterosexual 83 (40.5) 263 (28.7)
Other/unknown 22 (10.7) 76 (13.4)
Previous AIDS-defining events 55 (26.8) 187 (32.9) .114
CD4+ cell count, mean cells/mL  SD 69  82 135  170 !.001
Plasma HIV RNA load, mean log10
copies/mL  SD 4.68  1.13 4.40  1.32 .005
Prophylaxis against TE 35 (17.1) 171 (30.6) !.001
Cognitive symptoms 94 (45.9) 357 (62.9) !.001
Focal signs 149 (72.7) 262 (46.1) !.001
Abnormal mental status 69 (33.6) 156 (27.5) .074
Cerebral atrophy 31 (15.1) 244 (43.0) !.001
White matter involvement 60 (29.3) 316 (56.5) !.001
Single lesion 61 (29.7) 71 (32.6) .674
Contrast enhancement 194 (94.6) 115 (20.2) !.001
Mass effect 159 (77.5) 67 (11.8) !.001
History of antiretroviral therapy 76 (37.1) 293 (52.0) !.001
Receipt of antiretroviral therapy at diagnosis 50 (24.4) 207 (36.4) .002
NOTE. Data are no. (%) of patients, unless otherwise indicated. IDU, injection drug user;
MSM, man who has sex with men
toptic diagnosis of TE was obtained in 4.4% of cases, and a
presumptive diagnosis, made according to CDC criteria [18],
was obtained in 95.6%. Neuroimaging diagnosis was made on
the basis of CT and MRI findings in 66 (32.2%) of the patients,
CT findings alone in 97 (47.3%), and MRI findings alone in
42 (20.5%). Of the 568 patients classified as not having TE,
only 67 (11.8%) had a mass effect, and 56 of these patients
received a diagnosis of an alternative CNS disorder that was
confirmed by accepted criteria. In particular, the diagnoses were
progressive multifocal leukoencephalopathy (5 cases), primary
CNS lymphoma (26), cytomegalovirus encephalitis (1), cerebral
criptococcosis (6), CNS tuberculosis (4), and systemic non-
Hodgkin lymphoma with CNS involvement (5); 9 other dis-
orders were diagnosed, including neurosyphilis (1 case), men-
ingiomas (2), intracerebral hematoma (2), brain astrocitoma
(2), and pyogenic abscess (2). In the remaining 11 patients, an
encephalopathy of unknown origin, defined by the absence of
diagnostic criteria for the other disorders and by a defined
neuroradiological pattern, was described. Of these 11 patients,
5 had a CD4+ cell count of 200 cells/mL and a neuroimaging
pattern not suggestive of TE. Of the remaining 6 patients with
CD4+ cell counts of !200 cells/mL, only 2 had serological test
results positive for Toxoplasma species; however, in both cases,
TE has been reasonably excluded on the basis of clinical and
radiological findings and follow-up. Comparisons between the
demographic, clinical, virological, and neuroradiological char-
acteristics of patients with TE and patients without TE are
reported in table 1.
Baseline demographic, epidemiological, virological, clinical,
and radiological features for all patients, stratified according to
previous exposure to antiretroviral therapy, are reported in table
2. Previous exposure to antiretroviral therapy was found in 76
(36%) of the patients. Among patients who had experienced
antiretroviral therapy, 10 (13%) had received nucleoside re-
verse-transcriptase inhibitor monotherapy or double therapy,
with a median duration of exposure of 9 months (interquartile
range (IQR), 2–24 months), and 66 (87%) had received
HAART, with a median duration of exposure of 24 months
([IQR], 6–45 months). At neurological diagnosis, 44 (66%) of
the patients were receiving HAART, and 22 (34%) had discon-
tinued antiretroviral therapy. Virological parameters strongly
differed between the antiretroviral therapy–experienced and the
antiretroviral therapy–naive groups (table 2). Among patients
in the experienced group, an undetectable virus load in plasma
and a CD4+ cell count 1200 cells/mL at TE diagnosis were found
in 11% and 12% of patients, respectively. Patients in the ex-
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Table 2. Demographical, epidemiological, and clinical characteristics of 205 patients
at diagnosis of toxoplasmic encephalitis (TE), by history of antiretroviral (ART) exposure.
Variable
All patients
(n p 205)
ART-naive
patients
(n p 129)
ART-experienced
patients
(n p 76)
Male sex 135 (66.0) 84 (65.1) 51 (67.1)
Age, median years (IQR) 38 (34–43) 38 (33–43) 38 (35–42)
HIV transmission route
IDU 76 (37.1) 40 (31.0)a 36 (47.4)a
MSM 24 (11.7) 15 (11.6) 9 (11.8)
Heterosexual 83 (40.5) 58 (45.0) 25 (32.9)
Other/unknown 22 (10.7) 16 (12.4) 6 (7.9)
Previous AIDS defining events 55 (26.8) 12 (9.4)b 43 (56.6)b
CD4+ cell count, median cells/mL (IQR) 34 (15–101) 32 (15–73)a 45 (16–124)a
Plasma HIV RNA load, median
log10 copies/mL (IQR) 5.0 (4.4–5.4) 5.1 (4.7–5.5)
b 4.5 (2.7–5.2)b
TE prophylaxis 35 (17.1) 10 (7.8)b 25 (32.8)b
Clinical characteristics
Cognitive symptoms 94 (45.9) 59 (45.7) 35 (46.1)
Focal signs 149 (72.7) 97 (75.8) 52 (68.4)
Meningeal symptoms 16 (7.8) 11 (8.6) 5 (6.6)
Abnormal mental status 69 (33.6) 48 (37.5) 21 (27.6)
Neuroradiological characteristics
Cerebral atrophy 31 (15.1) 17 (13.9) 14 (18.4)
White matter involvement 60 (29.3) 42 (32.8) 18 (23.7)
Single lesion 61 (29.7) 35 (27.3) 26 (34.2)
Multiple lesions 141 (68.7) 91 (71.9) 50 (65.8)
Contrast enhancement 194 (94.6) 119 (93.0) 75(98.7)
Mass effect 159 (77.5) 101 (79.0) 58 (76.3)
NOTE. Data are no. (%) of patients, unless otherwise indicated. IDU, injection drug user; IQR, inter-
quartile range; MSM, man who has sex with men.
a P ! .05
b , by Fisher’s exact test and 1-way analysis of variance for categorical and continuous variables,P ! .01
as appropriate.
perienced group identified injection drug use as the HIV trans-
mission route more frequently (OR, 2.00; 95% CI, 1.11–3.59),
were more likely to have experienced a previous AIDS-defining
event (OR, 12.70; 95% CI, 6.01–26.82), and were more likely
to have been exposed to prophylaxis against TE (OR, 6.07; 95%
CI, 2.71–13.58). Prevalence of TE, stratified according to ex-
posure to antiretroviral therapy, as well by CD4+ cell count and
virus levels in plasma, is shown in figure 1.
Factors associated with TE. The relationship between the
risk of developing TE and different baseline factors is shown
in table 3. Male sex, previous exposure to antiretroviral therapy,
and higher CD4+ cell count at neurological diagnosis signifi-
cantly decreased the probability of TE according to multivariate
logistic regression analysis. The presence of lesions with contrast
enhancement or with mass effect was associated with a signif-
icantly higher risk of TE diagnosis, and detection of white
matter abnormalities was related to a decreased risk of disease.
Age, HIV transmission route, previous diagnosis of AIDS,
plasma HIV RNA load, and neurological features did not affect
the risk of TE occurrence.
TE prophylaxis was received by 35 (17%) of 205 patients.
Of note, as many as 31 (66%) of 47 patients who had expe-
rienced antiretroviral therapy and who had CD4+ cell counts
of !100 cells/mL were not receiving prophylaxis at the time of
TE diagnosis, even though 54% of them were currently pre-
scribed HAART. As shown in table 3, receipt of TE prophylaxis
independently reduced the risk of developing TE in the mul-
tivariate model.
TE follow-up. During the first 6 months after TE diagnosis,
the median duration of exposure to HAART was 150 days (IQR,
79–180 days). At 6 months, improvement and/or resolution of
disease was observed in 76% of patients during clinical ex-
amination and in 73.2% of patients according to CT and MRI
findings. The 6-month mean (SD) change in HIV RNA load
was log10 copies/mL, and the mean (SD) increase2.1 1.7
in CD4+ cell count was cells/mL (table 4).141.9 118.2
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Figure 1. Prevalence of toxoplasmic encephalitis (TE) among patients with neurological disorders, by history of exposure to antiretroviral therapy
(ART), CD4+ cell count, and plasma HIV RNA load (PVL) at onset of neurological disorder. Exp, patients with history of exposure to ART; naive, patients
with no history of exposure to ART.
Table 3. Baseline factors associated with the risk of developing toxoplasmic encephalitis (TE) by univariate or
multivariate logistic regression analysis in 805 patients with neurological disorders.
Variable
Univariate analysis Multivariate analysis
OR (95% CI) P OR (95% CI) P
Age 35 years 0.56 (0.38–0.81) .003 0.97 (0.51–1.87) .93
Sex, male vs. female 0.57 (0.40–0.81) .002 0.47 (0.25–0.88) .02
Transmission route, sexual transmission vs. IDU/unknown 1.68 (1.22–2.31) .002 1.23 (0.72–2.11) .45
ART status at TE diagnosis, experienced vs. naive 0.55 (0.39–0.76) !.001 0.49 (0.26–0.91) .02
History of TE prophylaxis 0.47 (0.31–0.71) !.001 0.47 (0.24–0.90) .02
Cognitive symptoms 0.50 (0.36–0.69) !.001 0.72 (0.40–1.29) .28
Focal signs 3.19 (2.24–4.52) !.001 1.08 (0.61–1.92) .79
Meningeal symptoms 0.37 (0.22–0.65) !.001 0.46 (0.20–1.05) .06
Cerebral atrophy 0.23 (0.15–0.35) !.001 0.78 (0.29–1.54) .47
Contrast enhancement 85.79 (42.65–172.54) !.001 30.45 (13.29–69.72) !.001
Mass effect 26.59 (17.51–40.37) !.001 5.17 (2.88–9.08) !.001
White matter involvement 0.33 (0.23–0.46) !.001 0.57 (0.33–0.98) .04
CD4+ cell count, cells/mL at TE diagnosisa 0.79 (0.72–0.87) !.001 0.85 (0.75–0.97) .01
Plasma HIV RNA load, log10 copies/mL at TE diagnosis
b 1.20 (1.05–1.38) .009 1.03 (0.81–1.30) .83
NOTE. IDU, injection drug use.
a For each increase in the CD4+ cell count of 50 cells/mL.
b For each increase in the plasma HIV RNA load of 1.0 log10 copies/mL.
On multivariable logistic regression analysis, the probability
of achieving 6-month clinical improvement and/or resolution
of disease was significantly lower in the antiretroviral therapy–
experienced patients than in the antiretroviral therapy–naive
patients (OR, 0.25; 95% CI, 0.16–0.39), even after adjusting
for CD4+ cell count, HIV RNA load, abnormal mental status,
number of brain lesions, prophylaxis against Toxoplasma spe-
cies, and duration of exposure to HAART after TE diagnosis.
Survival analysis. After a median follow-up period of 365
days (IQR, 180–545 days), a total of 34 patients (16.1%) died,
and 25 (73.5%) of these patients died during the first 6 months
of follow-up. In 22 cases, death was related to TE. During
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Table 4. Changes in CD4+ cell count and HIV RNA load and the clinical outcomes for 205 patients with
toxoplasma encephalitis (TE), by antiretroviral therapy (ART) status.
Variable
All patients
(n p 205)
ART–naive
patients
(n p 129)
ART–experienced
patients
(n p 76) Pa
Increase in CD4+ cell count, mean cells/mLSD 141.9  118.2 158.2  122.6 116.1  107.1 .06
Change in plasma HIV RNA load, mean log10
copies/mL  SD 2.1  1.7 2.81  1.37 0.97  1.70 !.001
Clinical improvement and/or resolution of TE
at 6 months after diagnosis, % of patients 76.0 87.5 58.1 !.001
a P values compare the ART-naive group with the ART-experienced group by 1-way analysis of variance for mean changes in CD4+
cell count and HIV RNA load and by Fisher’s exact test for frequency of 6-month clinical improvement and/or resolution of TE.
Table 5. Crude and adjusted relative hazards (RHs) for clinical progression of disease and for
death alone for 205 patients with toxoplasma encephalitis (TE), by univariate or multivariate Cox
regression analysis.
Variable
Univariate analysis Multivariate analysis
RH (95% CI) P RH (95% CI) P
Predictors of HIV progression
Cognitive symptoms 1.92 (1.12–3.25) .02 1.78 (1.00–3.14) .05
Abnormal mental status 2.08 (1.21–3.57) .008 1.55 (0.88–2.75) .13
CD4+ cell count 100 cells/mL 0.33 (0.13–0.82) .02 0.40 (0.15–1.02) .05
Multifocal lesions vs. single lesion 1.94 (1.00–3.77) .05 1.33 (0.67–2.64) .42
Receipt of HAART after diagnosis 0.22 (0.11–0.47) !.001 0.28 (0.13–0.61) .001
Predictors of death
Cognitive symptoms 2.18 (1.09–4.36) .03 1.62 (0.76–3.43) .21
Abnormal mental status 2.65 (1.35–5.20) .005 2.26 (1.10–4.64) .03
Plasma HIV RNA load 4 log10 copies/mL
a 1.62 (1.00–2.62) .05 1.38 (0.84–2.28) .20
Receipt of HAART after TE diagnosis 0.19 (0.08–0.45) !.001 0.21 (0.08–0.54) .001
NOTE. Clinical progression was defined as occurence of a new AIDS-defining event or death. Only variables
that were significantly associated with TE diagnosis on univariate Cox regression analysis were included in the
multivariate model.
a For each increase in the plasma HIV RNA load of 1.0 log10 copies/mL.
follow-up, there were 24 patients who experienced new AIDS-
defining events. The 1-year probability of clinical progression
of disease (i.e., the probability of experiencing a new AIDS-
related event or death) was 40%. According to the multivariate
Cox model, only the presence of cognitive symptoms was in-
dependently associated with an increased risk of HIV-related
disease progression, whereas a CD4+ cell count 100 cells/mL
and receipt of HAART after TE diagnosis (a time-dependent
covariate) were both associated with a reduced risk (table 5).
According to multivariate Cox regression, patients who initiated
HAART within 2 months after TE diagnosis had a significantly
decreased probability of HIV-associated disease progression,
compared with those who delayed therapy (relative hazard,
0.36; 95% CI, 0.15–0.86).
The 1-year estimated survival probability after TE diagnosis
was 77%. Analyzing the risk of death with use of the multi-
variable Cox model, the presence of abnormal mental status
was the only variable that was independently associated with
an increase in the risk of death, and receipt of HAART after
diagnosis was the only factor that was independently associated
with a decrease in the risk of death (table 5). Kaplan-Meier
curves displaying the probability of progression to AIDS or
death and to death alone according to prognostic variables are
shown in figure 2.
DISCUSSION
The results of our study indicate that, even in the late HAART
era, TE is still the most prevalent CNS disorder, accounting for
approximately one-fourth of all documented cases in both an-
tiretroviral-treated and untreated HIV-infected persons. This is
in accordance with the finding that the prevalence of this dis-
order among patients with focal brain lesions has remained
unchanged since the first years of the HAART era [9], even
though a reduction of incidence has been reported [5, 12]. This
apparent discordance between prevalence data and incidence
Figure 2. Kaplan-Meier estimated cumulative probability of surviving (left column) and of remaining free from clinical progression (CP) (right column)
in patients with toxoplasmic encephalitis (TE) by the main baseline prognostic factors (CD4+ cell count, plasma HIV RNA load, presence of cognitive
symptoms, abnormal mental status, and single or multiple focal brain lesions). CP was defined as any new AIDS-defining event or death. Significance
was tested with the log-rank test.
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data may be accounted for by a smaller decrease in the incidence
of TE, compared with other neurological disorders [5]. Con-
sidering that 36% of TE episodes occurred in persons with
previous exposure to antiretrovirals, patients who had experi-
enced antiretroviral therapy had a 50% reduction in risk of
developing TE. This effect was independent of HIV RNA load
and CD4+ cell count, confirming that the protective effect of
HAART against clinical progression is not simply related to
virological success [19]. Nevertheless, plasma virus levels were
comparably high and CD4+ cell count was consistently low both
in antiretroviral-naive and in antiretroviral-experienced pa-
tients, suggesting that the failure of treatment with antiretro-
virals is the main determinant when TE occurs in patients
receiving HAART. The fact that only 25% of patients developed
TE during the first 6 months of HAART (data not shown)
seems to suggest that the early risk due to incomplete recovery
of the immune system [20, 21] might not have represented a
relevant issue in our cohort.
A recent large prospective cohort study [12] showed that
lack of exposure to antiretroviral therapy and immunosup-
pression markers were strong predictors of TE occurrence. In
the present study, we found that, for each 50-cell decrease in
CD4+ cell count, there was a 30% increase in the risk of TE
occurrence, independent of antiretroviral exposure. It has been
suggested that a reduced risk of TE in the presence of HAART-
induced recovery of the immune system is associated with a
restoration of specific immune responses against Toxoplasma
gondii [22]. This observation has relevant implications for ther-
apeutic strategies, in particular for patients who remain strongly
immunodeficient despite HAART and are therefore still sus-
ceptible to opportunistic infections [12, 23].
The efficacy of primary prophylaxis in preventing TE is well
known [24–26]. In a comparative study by calendar years [12],
primary prophylaxis reduced the risk of TE by 46% in the early
HAART era. The present study confirmed the efficacy of pri-
mary prophylaxis in prevention of TE, with a 53% reduction
of the risk of TE occurrence. These results emphasize that, even
in the era of HAART, TE prophylaxis will remain a main factor
in reducing disease occurrence [8, 27]. Prophylaxis should be
discontinued in HAART-treated patients only when a sustained
rise in CD4+ cell count is detected [8, 28–32]; we observed that
only 34% of antiretroviral-experienced patients with a CD4+
cell count !100 cells/mL were receiving TE prophylaxis at di-
agnosis. On the basis of these data, survey studies about phy-
sician adherence to guidelines for the prevention of opportun-
istic infections in the HAART era may be advisable.
We could not entirely account for the increased risk of TE
observed in women independent from HAART exposure, vi-
rological markers, and TE prophylaxis. Female sex has been
associated with lower HIV loads in plasma, but significant sex-
based differences in rates of disease progression have been ex-
cluded [33, 34]. Furthermore, a higher rate of discontinuation
of therapy because of toxicity or likely poor adherence was
observed in HIV-infected women starting antiretroviral therapy
[35], even though sex was not generally associated with ad-
herence to HAART in most studies [36]. Female sex as a factor
increasing the risk of TE should be elucidated further.
Survival analysis showed that TE occurrence still represents
a poor prognostic determinant in the natural history of HIV-
infected persons, even in the era of HAART. In our cohort, the
estimated 1-year probabilities of showing HIV disease pro-
gression or death were 40% and 23%, respectively. This finding
is consistent with that observed among patients with AIDS and
multiple adverse prognostic factors in a large cohort of anti-
retroviral-naive patients starting HAART [37]. It is reasonable
to assume that, even though HAART remains the main prog-
nostic determinant in patients with advanced disease and severe
immunodeficiency [15, 38], TE-specific mortality had a relevant
role in negatively affecting survival, accounting for more than
two-thirds of all deaths. However, in our study, starting HAART
after TE diagnosis was associated with a strong reduction of
the risk of clinical progression of disease and death, and this
is consistent with the dramatic improvement in survival rates
observed in patients with advanced disease when adjusted for
HAART adherence and appropriate care [39]. Considering the
calendar years of the present study, it is conceivable that our
cohort could have benefited from the improvements in anti-
retroviral regimens and HAART management that have been
observed in recent years for HIV-infected persons with very
advanced disease [40].
We further observed a significant benefit of early initiation
of HAART after TE diagnosis. In fact, a 3-fold reduction in
the risk of developing a new AIDS-defining event or death in
patients who started HAART within the first 2 months after
diagnosis of a neurological disorder has been found. An un-
resolved question, raised in the past several years, concerned
the appropriate timing for initiation of HAART in patients with
opportunistic diseases. Even though a potential benefit in treat-
ing certain AIDS-related conditions has been shown [41, 42],
relevant concerns relative to the toxicity of multiple-drug reg-
imens and poor adherence have supported delaying the initi-
ation of HAART until after the acute phase of most oppor-
tunistic diseases. Even though we are not able to determine the
optimum timing for starting HAART after TE diagnosis, it
seems that early initiation of HAART leads to a survival benefit.
Some limitations of this study need to be mentioned. First,
classification bias could not be entirely excluded because TE
diagnoses were formulated by the treating physician at the par-
ticipating center. However, diagnostic criteria were standardized
in the study design, according to updated literature, and the
methods that were employed were specified in each notification
sheet. The Coordinating Center revised all notified sheets and
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certified the appropriate definition criteria employed, and all
discordant cases were excluded. A second limitation of the study
was that information about serological testing for Toxoplasma
species was only included among the diagnostic criteria of TE
and was not specifically required on the notification sheet for
other diagnoses. The lack of this finding may have affected a
complete evaluation of prophylaxis data. Nevertheless, previous
data showed that only 3%–6% of patients with TE had negative
results of serological tests [43], and this could have minimized
possible bias in the analysis. Furthermore, previous data suggest
that, in the Italian population, the rate of primary infection
with Toxoplasma species did not increase as a result of an in-
crease in the rate of AIDS [44], as confirmed by the very low
prevalence of detection of IgM-specific antibody response in
HIV-infected people. On the basis of these considerations, we
think that a lack of serological testing for infection with Tox-
oplasma species would not have significantly influenced the
accuracy of the epidemiological data in our study.
Finally, we cannot estimate the exact prognostic impact of
TE on survival because of a lack of control subjects with ad-
vanced HIV infection who did not have neurological disease.
However, prevalent data allow more-accurate comparative
analyses within a group of subjects who are homogeneous for
clinical selection criteria, and this method is more appropriate
for acquiring clinical information.
In conclusion, TE remains the most prevalent cause of HIV-
associated neurological disorders, even in the late HAART era,
with an increased risk of disease observed in antiretroviral-naive
patients. Severe immunodeficiency and a lack of TE prophylaxis
were confirmed as main determinants of TE occurrence, in-
dependent of whether HAART was received. Moreover, even if
receipt of HAART after diagnosis with a neurological disorder
markedly reduced the risk of clinical progression and death—
particularly if started early in the course of neurological dis-
ease—TE survival remained poor, mainly for early specific mor-
tality. Because TE was associated with a high probability of
early death, all strategies to avoid TE occurrence, such as not
delaying HAART until there is a high risk of clinical progression
and maintaining prophylaxis in immunosuppressed patients for
whom HAART has failed, should be considered [45–47].
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